The purpose of this article is to summarize the current knowledge about treatment with oral platelet inhibitors in patients with acute coronary syndrome (ACS). Antiplatelet therapy has been shown to improve the prognosis of patients with ACS with ST segment elevation myocardial infarction (STEMI) and non-ST segment elevation ACS (NSTE-ACS). Aspirin should be given with a loading dose of 250-500 mg, followed by 75-100 mg/day. Dual antiplatelet therapy is recommended for all patients with ACS for 12 months regardless of the initial revascularization strategy. Clopidogrel should be administered at first medical contact in STEMI with a loading dose of 600 mg. In patients with ACS and percutaneous coronary intervention (PCI) 2 9 75 mg clopidogrel should be given daily over 7 days, while in all other patients 75 mg per day appears to be sufficient. The two newer adenosine diphosphate-receptor antagonists prasugrel and ticagrelor lead to a more rapid and effective inhibition of platelet aggregation compared with clopidogrel, which was associated with an improved clinical outcome in two large randomized studies. Prasugrel is indicated in patients with ACS undergoing PCI and was most effective in diabetics and in patients with STEMI. In the recent TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes trial in medically treated patients with NSTE-ACS, prasugrel did not significantly reduce ischemic events compared with clopidogrel. Ticagrelor has been studied in the whole spectrum of ACS patients and reduced cardiovascular and total mortality in comparison with clopidogrel. The greatest benefit has been observed in patients with planned conservative treatment and in patients with impaired renal function.
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ASPIRIN
Aspirin is one of the most frequently studied drugs and has been shown to improve prognosis in patients with STEMI and NSTE-ACS [3] . With a loading dose of 250-500 mg (orally or, as preferred in Europe, intravenously), inhibition of the cyclooxygenase A and attenuation of thromboxane A 2 is achieved within minutes.
While in the US a maintenance dose of 325 mg has been preferred, in most European countries 100 mg is the standard. In the large Clopidogrel optimal loading dose Usage to Reduce Recurrent EveNTs/Optimal Antiplatelet Strategy for InterventionS (CURRENT-OASIS) 7 trial [4] a dose of 75-100 mg was as effective as 300-325 mg with respect to ischemic events after 30 days, but associated with a reduction in minor bleedings (Table 1) . It should be acknowledged that patients in the CURRENT-OASIS 7 trial were a low-risk group, indicated by the low combined endpoint rate of 4.3% after 30 days [4] . Therefore, it cannot be ruled out [5] . However, a 600 mg loading dose is associated with a faster onset and higher level of platelet aggregation inhibition [6] . In the already mentioned CURRENT-OASIS 7 trial, the 600 mg loading dose followed by 2 9 75 mg daily over 7 days reduced ischemic events in patients with ACS treated with percutaneous coronary intervention (PCI), compared with the standard dose [7] . In the patients without PCI there was no benefit of the double-dose clopidogrel [4] ( Table 2 ).
The optimal timing of initiation of clopidogrel therapy is still a matter of debate. In patients with STEMI and planned primary PCI the results of a small randomized trial [8] and large registries [9] suggest that the loading dose should be given at first medical contact, preferably in the prehospital phase in the ambulance. Since only very few patients with STEMI will be referred for immediate coronary artery bypass surgery, the risk of severe bleeding is not significantly increased with the prehospital loading dose.
Clopidogrel has several drawbacks: the delayed onset of action, the large interindividual variability in platelet response, and its irreversible effect on platelet inhibition [6] . The first two points are due to the two-stage activation process of clopidogrel, involving a number of cytochrome P450 isoenzymes, which are susceptible to drug-drug interactions and genetic polymorphisms. Patients with genetic polymorphisms have a reduced or a lack of metabolism of clopidogrel, and might therefore be good candidates for treatment with newer compounds [10] .
Two new compounds, the nonreversible thienopyridine prasugrel and the reversible cyclopentyl-triazolo-pyrimidine, ticagrelor, lead to a faster and more potent ADP-receptor inhibition, compared with clopidogrel [11, 12] .
While prasugrel needs only one metabolization step, ticagrelor is an active drug which does not need metabolization to become active. In two large trials they were compared with the standard clopidogrel dose (300 mg loading dose followed by 75 mg) and were able to reduce the primary endpoint of cardiovascular death, myocardial infarction, and stroke significantly [13, 14] ( There were important differences in design and patients between the two trials. In TRITON-TIMI 38 only ADP-receptor antagonist-naïve patients with NSTE-ACS and known coronary artery anatomy undergoing PCI and patients with STEMI scheduled for primary PCI were included. In contrast, in the PLATO trial, patients with the whole spectrum of ACS, regardless of the initial strategy were enrolled.
Half of the patients were already pretreated with clopidogrel. Therefore, the results of these two trials cannot be compared directly. The 1-year cardiovascular mortality was lower in TRITON-TIMI 38 compared with PLATO (2.2% vs. 4.5%).
The PLATO trial included a higher-risk group of ACS patients. However, in the PLATO trial a significant reduction in cardiovascular mortality (4.0% vs. 5.1%, P = 0.001) and allcause mortality (4.5% vs. 5.9%, P = 0.0003) was observed. Patients with an impaired renal function had particular benefit from ticagrelor [15] . An important subgroup was the patients undergoing coronary artery bypass surgery [16] .
Here, ticagrelor reduced total mortality from 9.7% to 4.7% (P\0.01), without an increase in major bleeding complications. Patients with an intended conservative therapy also benefitted from ticagrelor [14] . The question as to whether ticagrelor should be given at first medical contact in patients with STEMI scheduled for primary PCI is currently being investigated in the randomized Administration of Ticagrelor in the Catheterization Lab or in the Ambulance for The results with prasugrel were particularly impressive in patients with STEMI [17] and with diabetes mellitus [18] . A subgroup in which prasugrel was associated with an unfavorable outcome are the patients with prior stroke/transient ischemic attack (TIA). In these patients, prasugrel is contraindicated. Fig. 1 [20] . Therefore, the optimal timepoint for administration of the loading dose of prasugrel in NSTE-ACS seems to be after visualization of coronary anatomy and the decision to proceed to PCI.
Both studies have been criticized because of the low loading dose of clopidogrel (300 mg), which certainly is associated with a delayed onset of action compared with the 600 mg dose [6] . This applies somewhat more to the TRITON-TIMI 38 study where all patients were ADPreceptor antagonist naïve. However, in the CURRENT-OASIS 7 trial the differences between the 300 and 600 mg loading dose were overall statistically negative [3] and not in the magnitude observed between prasugrel and clopidogrel in the TRITON-TIMI 38 trial [13] . In the ACAPULCO study, the 600 mg loading dose of clopidogrel was not as effective as prasugrel in patients with ACS [11] . In the PLATO trial the benefit of ticagrelor was somewhat delayed and the curves continued to diverge during the followup period, so a significant contribution of the loading dose is unlikely. In addition, almost half of the patients had received a clopidogrel loading dose before randomization, and in In summary, the newer ADP-receptor antagonists, prasugrel and ticagrelor, are able to achieve a more rapid and effective inhibition of platelet aggregation compared with clopidogrel. This is associated with a 1.9-2.2% absolute and 16-19% relative-risk reduction for Cardiol Ther (2013) 2:47-56 51 ischemic events, but with an increase of TIMI major noncoronary artery bypass graft (CABG)-related bleeding of 0.6%. Data looking at these new compounds in patients with the need for oral anticoagulation is lacking, therefore in those patients clopidogrel should be given.
Other patient populations where we need more data regarding safety and efficacy of the new drugs are the elderly, patients with prior stroke (especially hemorrhagic stroke), and those with severe comorbidities, who were not included in the large randomized trials. For these patients, real-world data from large wellperformed registries are needed to determine the safety and efficacy in clinical practice. 
PLATELET THROMBIN RECEPTOR ANTAGONISTS

THE PROBLEM OF BLEEDING DEFINITIONS
In recent years it has become clear that not only the ischemic events but also bleeding contribute to the mortality of patients with ACS. If antiplatelet treatment becomes more intense and effective, this is usually associated with an increase in bleeding complications. In order to be able to compare the efficacy and safety of new antiplatelet regimens, a unique definition of bleeding complications would be desirable [27] . Unfortunately, large clinical trials have used different definitions for bleedings [28] . In Table 3 , bleeding complications in the different large clinical trials with oral antiplatelet therapy for ACS patients are summarized.
In Fig. 2 the non-CABG-related major bleeding rates after 30 days are depicted.
Looking at Table 3 and Fig. 2 it becomes clear that the rate of CABG procedures and the definition of bleeding complications contribute majorly to the bleeding rates.
Therefore, it seems rather difficult to compare bleeding complication rates between the trials.
The commonly used comparator therapy was aspirin and the standard therapy was clopidogrel (300/75 mg). With this therapy, bleeding rates were by far not identical in the trials, again underscoring the problems of comparing therapies indirectly. Overall, the results show that a more effective platelet inhibition is associated with higher bleeding rates. 
